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Summary Five anthracycline derivatives, i.e. doxorubicin, epirubicin, pirarubicin, aclarubicin and a new
fluorinated anthracycline derivative (ME2303), were tested for antitumour activity in mice with hepatic
neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26. Intravenous administrations of
pirarubicin and ME2303 on day 4 or days 4, 8 and 12 in mice with hepatic neoplastic nodules of Lewis lung
carcinoma rendered more than 50% of mice tumour-free over wide ranges of nontoxic doses, whereas a few
mice were cured by treatment with doxorubicin and no mice were cured by treatment with epirubicin or
aclarubicin. Moreover, when ME2303 was administered at 50 mg kg-' on days 7, 11 and 15 to six mice
bearing more advanced hepatic tumours, five were cured, while pirarubicin and doxorubicin never achieved
cure. Furthermore, in mice with hepatic neoplastic nodules of colon adenocarcinoma 26, ME2303 also showed
a marked antitumour effect compared to pirarubicin or doxorubicin. Two or three injections of ME2303
starting from day 7 conferred a greater antitumour effect than did more fractionated or single-dose regimens.
Doxorubicin is widely used as a chemotherapeutic agent
against various human neoplasms, and it shows impressive
anti-tumour activities. However, its use is restricted due to its
cardiotoxic and undesirable side effects. In order to improve
the pharmacodynamic properties of clinically-useful anti-
tumour anthracyclines, new doxorubicin analogues that have
lower toxicity but higher antitumour activity have been syn-
thesised or isolated (Oki et al., 1975; Umezawa et al., 1979;
Cassinelli et al., 1984; Weiss et al., 1987; Arcamone, 1987;
Israel et al., 1987). In Japan, the presently-used anthracycline
derivatives are doxorubicin, epirubicin, pirarubicin,
aclarubicin and daunorubicin. Recently, Tsuchiya et al.
(1986, 1988) reported ME2303 (Figure 1), a 2-fluoroglycoside
of doxorubicin, which is more resistant to hydrolysis to
aglycones and shows marked antitumour effects.
The liver is the primary site of metabolism of many drugs.
The doxorubicin level in the liver is 100-fold higher than that
in the plasma (Iguchi et al., 1985). It would be interesting to
know which anthracycline derivative is the most active
against tumours in the liver. Moreover, ME2303 is quite
resistant to hydrolysis to aglycones, and may be expected to
be particularly effective against such tumours. Therefore,
artificial hepatic 'metastases' (hepatic neoplastic nodules)
were produced in mice by intrasplenic injection of Lewis lung
carcinoma or colon adenocarcinoma 26 cells, and we then
investigated the antitumour effects of various anthracycline
derivatives.
Materials and methods
Chemicals
Doxorubicin and epirubicin were purchased from Kyowa
Hakko Kogyo Co. Ltd, Tokyo, Japan. Pirarubicin and
ME2303 were provided by Meiji Seika Kaisha Ltd, Tokyo.
Aclarubicin was purchased from Sanraku-Ocean Co. Ltd,
Tokyo.
Animals
Groups of six more specific pathogen-free male BDF, or
CDF, mice weighing 22-24 g (Japan SLC, Inc.; Hamamatsu,
Japan) were housed in plastic cages with wood chip bedding
and were provided CA-1 pellet diets (CLEA Japan, Inc:
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Figure 1 Structure of ME2303.
Tokyo, Japan) and water ad libitum. All experiments were
performed in an animal laboratory at a controlled
temperature (25°C).
Experimentalprocedurefor inducing hepatic neoplastic nodules
Lewis lung carcinoma and colon adenocarcinoma 26 were
maintained in male C57BL/6 and Balb/c mice, respectively.
Cell suspensions of Lewis lung carcinoma and colon adeno-
carcinoma 26 in saline were prepared from surgically-
removed corresponding tumours by disaggregating tumour
pieces by gentle homogenisation in a loosely fitted glass
homogeniser, and the cell suspension was passed through a
120-mesh sieve. Multiple hepatic neoplastic nodules were
produced according to the method of Kopper et al. (1982).
Mice were anesthetised with ether, a left subcostal incision
(about 5 mm) was made, and the spleen was externalised. A
27-gauge needle (Terumo Japan, Tokyo) was used to punc-
ture the splenic capsule, and 5 x 104 viable tumour cells in
0.1 ml of saline were injected directly into the upper role of
the spleen. Gentle pressure was applied for a period of 10 s
to prevent hemorrhage and tumour cell extravasation. The
arteria and vena linealis were then clamped with a medium
hemoclip (Edward Weck & Co, Inc, NC), and the spleen was
removed. The abdomen was stitched with surgical sutures,
and the skin was closed with disposable skin clip applicators
(Avlox 12, Medi Plast, Sweden). The mice were allowed to
recover and were then randomised before being distributed to
groups.
Drug treatment
Drugs were dissolved in 0.9% saline solution. The drugs were
injected i.v. only on day 4, on days 4, 8 and 12 or on days 7,
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11 and 15. Moreover, to determine the best treatment
schedule of ME2303, the drug was injected i.v. using a 27
gauge needle (Terumo Japan, Tokyo) with gentle pressure in
single (100 mg kg-', day 7) and fractionated-dose regimens
(S0mg kg-' x 2, 33 mg kg-' x 3, 20 mg kg-' x 5 and 11 mg
kg- ' x 9). The injection volume was 0.01 ml g-' body weight.
Observation was terminated on day 80. All mice surviving at
that time were recorded as 'cured'. The antitumour effect was
determined by comparing the mean survival time of each
treated group with that of the control group and expressed as
the increase in life-span (ILS). At death, the mice were
examined for the presence of hepatic neoplastic nodules.
Cured mice were excluded from the mean survival time cal-
culation.
Statistical analysis
The t-test for small samples was used to determine the statis-
tical significance of differences; P<0.05 was considered
significant.
Results
Antitumour effects ofanthracycline derivatives on hepatic
neoplastic nodules ofLewis lung carcinoma-bearing mice
Hepatic neoplastic nodules were created by intrasplenic
inoculation of tumour cells. Under light microscopy, liver
micronodules were clearly recognised on the 7th day after
tumour cell inoculation of Lewis lung carcinoma and on the
4th day for colon adenocarcinoma 26. The liver weight at
death was 3.24±0.11 g (n=67) or 5.42±0.26g (n=21) in
Lewis lung carcinoma or colon adenocarcinoma 26-bearing
mice, whereas that ofnormal mice was 0.99 ± 0.01 g (n = 60).
If untreated, all the mice died after approximately 20 days
with many nodules in the liver.
The antitumour effects of five anthracycline derivatives
(doxorubicin, epirubicin, pirarubicin, aclarubicin and
ME2303) administered on day 4 or days 4, 8 and 12 were
evaluated against established multiple murine hepatic nodules
of Lewis lung carcinoma. The results of these anthracycline
derivatives on this tumour system are shown in Table I. Two
of six mice were cured by a single injection ofdoxorubicin on
day 4 at 12.5 mg kg-', which was the best treatment protocol
for doxorubicin. However, more than 50% of the mice were
cured by pirarubicin at between 12.5 and 25mgkg-' in a
single injection and 6.3mgkg-' t.i.d.
Moreover, more than 50% of the mice were cured by
ME2303 at between 25 and 100 mg kg' in a single injection
and between 25 and 50 mg kg-' t.i.d., whereas no cured mice
were recorded with epirubicin or aclarubicin. When therapy
was initiated on day 7, ME2303 at 50 mg kg-' t.i.d. was also
effective, and higher rates of cure (5/6) were obtained, while
doxorubicin and pirarubicin showed no cases of cure (Table
II). The effect of pirarubicin initiated on day 7 was not as
good as that obtained with treatment initiated on day 4. The
effects of doxorubicin and pirarubicin decreased with the
delay in the treatment. These observations clearly demon-
strate the superiority of ME2303 over doxorubicin and pira-
rubicin in therapeutic efficacy against hepatic nodules of
Lewis lung carcinoma.
Table I Effect of anthracycline derivatives on hepatic
carcinoma
nodules of Lewis lung
Dose Treatment MSP ILS No. ofcured
Drugs (mgkg-') schedule (days) (%) miceb
Control 21.4±1.3c 0/15
Doxorubicin 25 Day 4 50.4±2.9 136 0/6
12.5 55.8± 7.5 161 2/6
6.3 25.1±2.0 17 0/7
12.5 Days 4, 8, 12 18.0±0.6 -16 0/6
6.3 28.6±2.8 34 1/6
3.2 19.8±0.8 -7 0/6
Control 20.5± 1.6 0/6
Epirubicin 50 Day 4 10.7±0.4 -48 0/6
25 35.8±2.0 75 0/6
12.5 26.5±0.6 29 0/6
12.5 Days 4, 8, 12 35.7±2.3 74 0/6
6.3 26.8±1.2 31 0/6
3.2 23.3± 1.3 14 0/6
Control 20.2± 1.4 0/6
Pirarubicin 25 Days 4 4/6
12.5 5/6
6.3 38.8±3.1 92 2/6
6.3 Days 4, 8, 12 6/6
3.2 42.8±5.8 112 1/6
1.6 23.8±1.3 18 0/6
Control 19.4± 1.5 0/6
Aclarubicin 50 Day 4 8.5± 0.2 -56 0/6
25 27.2± 1.4 40 0/6
12.5 19.7± 1.3 2 0/6
12.5 Days 4, 8, 12 24.2±2.4 25 0/6
6.3 25.0± 1.4 29 0/6
3.2 22.2± 1.6 14 0/6
Control 18.8± 1.7 0/10
ME2303 100 Day 4 37.3±9.7 98 9/12
75 50.0±5.0 166 3/6
50 40.7±3.8 116 8/11
25 4/6
50 Days 4, 8, 12 6/6
25 6/6
12.5 37.3± 6.4 98 1/6
6.3 27.2± 1.8 45 0/6
'MST, mean survival timeofdeceased mice.bNumberofcuredmicepertreated mice, on
day 80. cMean± s.e.ANTITUMOUR EFFECT OF ANTHRACYCLINES 365
Table II Effect of anthracycline derivatives on advanced hepatic
nodules of Lewis lung carcinoma
Dose MSP ILS No. of
Drugs (mgkg-') (days) (%) curedmiceb
Control 17.6±0.8c 0/10
Doxorubicin 6.3 25.2±2.2d 43 0/6
3.2 16.5±1.0 -6 0/6
Pirarubicin 12.5 20.0±0.8 14 0/6
6.3 33.4 1.3e 90 0/6
3.2 25.0+2.0e 42 0/6
ME2303 50 5/6
25 39.8 1.6e 126 1/6
12.5 29.3 0.8e 66 0/6
Lewis lung carcinoma cells were inoculated into the liver by intra-
splenic inoculation, and drugs were administered i.v. on days 7, 11 and
15. 'MST, mean survival time ofdeceased mice; bNumber ofcured mice
per treated mice, on day 80; cMean+s.e.; dP<0.01 compared to
Control; ep<0.001.
Antitumour effect ofanthracycline derivatives on hepatic
neoplastic nodules ofcolon adenocarcinoma 26-bearing mice
For this study, we used colon adenocarcinoma 26 tumour
cells. The hepatic neoplastic nodules showed a different
histology from the nodules of Lewis lung carcinoma cells
following intrasplenic inoculation. Micronodules of colon
adenocarcinoma 26 were already found in the liver on day 4
(Figure 2). The antitumour effects ofdoxorubicin, pirarubicin
Figure 2 Liver tissue sections obtained from mice intra-
splenically injected with colon adenocarcinoma 26 on the 4th a,
and 7th b days of tumour evolution. Haematoxylin and eosin
x 170.
and ME2303 were examined in mice with intrasplenic inocu-
lation of colon adenocarcinoma 26. There were few cases of
complete tumour regression in these drug-treated mice on
days 7, 11 and 15. The maximum ILSs of doxorubicin,
pirarubicin and ME2303 were 58, 31 and 191%, respectively
(Table III). ME2303 showed the strongest antitumour effect
against this liver tumour.
Influence oftreatment schedule ofME2303
To obtain more effective treatment with ME2303, the influ-
ence of the treatment schedule on the hepatic nodules of
colon adenocarcinoma 26-bearing mice was investigated.
With a total dose of 100 mg kg-' i.v., two- and three-fraction
dose regimens showed greater efficacy compared to the single
treatment regimen (Table IV). The five-fraction regimen
(every other day) caused toxic death. The nine-fraction dose
regimen (days 7-15 daily) also showed toxicity, but the
toxicity of this regimen was weaker than that of the five-
fraction dose regimen (days 7, 9, 11, 13 and 15). The body
weight of the mice recovered after more than 2 weeks after
stopping the treatment, but the hepatic neoplastic nodules
regrew. Moreover, when compared with three- and five-
fraction dose regimens in normal CDF, mice treated with
same total doses of ME2303, the body weight with the
five-fraction regimen was markedly decreased compared with
the three-fraction regimen (Figure 3), like in tumour-bearing
mice. This result means that the three-fraction dose regimen
is lower in toxicity than the five-fraction regimen.
Discussion
In this study, we investigated the antitumour effect of five
anthracycline derivatives (doxorubicin, epirubicin, pirarub-
icin, aclarubicin and ME2303) against hepatic nodules of
Lewis lung carcinoma and colon adenocarcinoma'26. The
hepatic nodules of Lewis lung carcinoma were well inhibited
by pirarubicin and ME2303. These drugs produced many
'cured' mice when the drugs were injected on day 4 or on
days 4, 8 and 12, while there were only a few cured mice in
the group treated with doxorubicin using the same schedule.
Table III Effect of anthracycline derivatives on advanced hepatic
nodules of colon adenocarcinoma 26
Dose MS7T ILS No. of
Drugs (mgkg-') (days) (%) curedmice"
Control 16.0± 0.7c 0/6
Doxorubicin 6.3 21.5±2.6 34 1/7
3.2 25.3± 3.9d 58 0/7
Pirarubicin 12.5 20.0± 1.8 25 0/7
6.3 21.0±0.7e 31 0/7
3.2 17.6±0.7 10 0/7
ME2303 50 46.6 2.1 e 191 1/7
25 28.1±2.ff 76 0/7
12.5 21.7±3.If 36 0/7
Colon adenocarcinoma 26 cells were inoculated into the liver by
intrasplenic inoculation, and drugs were administered i.v. on days 7, 11
and 15. aMST, mean survival time ofdeceased mice; bNumber ofcured
mice per treated mice, on day 80; cMean +s.e.; dp<0.05 compared to
Control; eP<0.01; fp<0.0i.
Table IV Influence of treatment schedule of ME2303 on advanced
hepatic nodules of colon adenocarcinoma 26
Dose
(mgkg' Treatment Mean survival ILS Liver weight
day-') schedule time (days) (%) at death (g)
Control 19.6± 1.4a 5.01 ±0.47a
100 Day 7 24.6± 10b 26 4.66±0.31
50 Days 7, 11 44.6±6.1c 128 4.23±0.40
33 Days 7, 11, 15 49.3±7.Id 152 3.72±0.49
20 Days7,9, 11, 13, 15 17.9±0.5 -9 1.08±0.29
11 Days 7-15, daily 29.1±3.2b 48 3.58±0.55
aMean± s.e. ofsevenmice;bp<0.05comparedtoControl;cP<0.01;
dP = 0.001.366 M. IIGO et al.
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Figure 3 Effect on body weight of normal CDF1 mice in the
three a and five- b fractionated dosage regimens of ME2303.
Results are mean±s.e. of six mice + (dead mice/total number of
mice). In a, -0-, Control; -*-, 75 mg kg-' day-'; A-,
50 mg kg-'day-'; -A-, 30 mg kg-' day-'; -*-, 15 mg kg-'
day-'. In b, -0-, Control; -*-, 45mgkg-' day-'; -A
30mgkg-'day-'; -A-, 18mgkg-'day'; -*-, 9mgkg-'
day-'.
On the other hand, no mice were cured by treatment with
epirubicin or aclarubicin. Moreover, delayed treatment with
doxorubicin, pirarubicin and ME2303, on days 7, 11, and 15,
showed much more different effect on survival of the tumour-
bearing mice. Many mice were cured by the optimal dose of
ME2303, but none were cured by any dose of doxorubicin or
pirarubicin.
Thus, ME2303 resulted in many cured mice even in the
advanced stage of hepatic neoplastic nodules, while in the
treatment of doxorubicin and pirarubicin cured mice were
observed at high frequency only in the early stage of tumour
growth in the liver.
When the therapeutic ratio (the dose showing maximum
ILS/the dose showing 30% ILS) (Hoshi et al., 1976) was
calculated from Table II, those of doxorubicin, pirarubicin
and ME2303 were about 1.2, 2.3 and 6.0, respectively. Thus,
the therapeutic ratio of ME2303 was 5-fold greater than that
of doxorubicin. Moreover, using the hepatic nodule model of
colon adenocarcinoma 26, we found that ME2303 also shows
a superior antitumour effect compared with doxorubicin and
pirarubicin. Namely, the ILS with ME2303 was greater than
that with doxorubicin at optimal doses by i.v. administration,
although there were few mice cured by the treatment with
these anthracycline derivatives. Thus, ME2303 was the most
active agent in mice with hepatic nodules of both Lewis lung
carcinoma and colon adenocarcinoma 26, while doxorubicin
was not very effective. As the optimal treatment regimen,
three injections, every 4th day, may be considered in the
chemotherapy of liver tumours. Greater fractionation of the
dosage regimen and a shorter interval between doses were
observed to cause lethal toxicity in many mice.
In an in vitro experiment (Tsuruo et al., 1989), ME2303
had a cytotoxic effect similar to that of doxorubicin against
P388 leukemia, and ME2303 showed a marked antitumour
effect against i.p.-inoculated tumour cells compared to doxo-
rubicin. Although in vitro experiments on ME2303 have not
been performed against the Lewis lung carcinoma and colon
adenocarcinoma 26 cell lines, ME2303's antimetastatic effect
may be due to better delivery of the drug to the tumour in
the liver.
This work was supported in part by a Grant-in-Aid for Cancer
Research (1-10) from the Ministry of Health and Welfare.
We thank Ms H. Morinaga for her expert secretarial assistance.
References
ARCAMONE, F. (1987). Clinically useful doxorubicin analogues.
Cancer Treat. Rev., 14, 159.
CASSINELLI, G., CONFIGLIACCHI, E., PENCO, S. & 4 others (1984).
Separation, characterization and analysis of epirubicin (4'-epi-
doxorubicin) and its metabolites from human urine. Drug Metab.
Disp., 12, 506.
HOSHI, A., IIGO, M., NAKAMURA, A., YOSHIDA, M. & KURETANI,
K. (1976). Antitumour activity of 1-hexylcarbamoyl-5-fluorouracil
in a variety of experimental tumors. Gann, 67, 725.
IGUCHI, H., TONE, H., ISHIKURA, T., TAKEUCHI, T. & UMEZAWA,
H. (1985). Pharmacokinetics and disposition of 4'-O-tetrahydro-
pyranyladriamycin in mice by HPLC analysis. Cancer Chemother.
Pharmacol., 15, 132.
ISRAEL, M., SESHADRI, R., KASEKI, Y., SWEATMAN, T.W. & IDRISS,
J.M. (1987). Amelioration of adriamycin toxicity through modi-
fication of drug-DNA binding properties. Cancer Treat Rev., 14,
163.
KOPPER, L., HANH, T.V. & LAPIS, K. (1982). Experimental model for
liver metastasis formation using Lewis lung tumor. J. Cancer Res.
Clin. Oncol., 103, 31.
OKI, T., MATSUZAWA, Y., YOSHIMOTO, A. & 10 others (1975). New
antitumour antibiotics, aclacinomycins A and B. J. Antibiotics,
28, 830.
TSUCHIYA, T., TAKAGI, Y., OK, K. & 4 others (1986). Syntheses and
antitumour activities of 7-0-(2,6-dideoxy-2-fluoro-a-L-talopyran-
osyl) adriamycinone. J. Antibiotics, 39, 731.
TSUCHIYA, T., TAKAGI, Y., UMEZAWA, S. & 6 others (1988). Syn-
thesis and antitumour activities of 14-0-acyl derivatives of 7-0-
(2,6-dideoxy-2-fluoro-a-L-talopyranosyl) adriamycin. J. Antibio-
tics, 41, 988.
TSURUO, T., YUSA, K., SUDO, Y., TAKAMORI, R. & SUGIMOTO, Y.
(1989). A fluorine-containing anthracycline (ME2303) as a new
antitumour agent against murine and human tumors and their
multidrug-resistant sublines. Cancer Res., 49, 5537.
UMEZAWA, H., TAKAHASHI, Y., KINOSHITA, M. & 5 others (1979).
Tetrahydropyranyl derivatives of daunomycin and adriamycin. J.
Antibiotics, 32, 1082.
WEISS, R.B., SAROSY, G., CLAGETT-CARR, K., RUSSO, M. & LEY-
LAND-JONES, B. (1987). Anthracycline analogues: the past, pres-
ent and future. Cancer Chemother. Pharmacol., 18, 185.